The U.S. Food and Drug Administration (FDA) sent over 50 warning letters to GLP-1 drug compounders and manufacturers in September 2025. The agency warned the companies that their statements that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback